TC
ZNTL icon

TwinBeech Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

TwinBeech Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-128,859
Closed -$2.58M – 942
2023
Q3 		$2.58M Buy
+128,859
New +$3.27M 0.05% 367
2022
Q4 		– Sell
-28,027
Closed -$607K – 975
2022
Q3 		$607K Buy
+28,027
New +$766K 0.02% 500

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

TwinBeech Capital's ZNTL Position: Q4 2023 in Review

TwinBeech Capital sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2023, closing a stake of 128,859 shares — an estimated $2.58M sold.

TwinBeech Capital first reported a position in ZNTL in Q3 2022 and held it in 2 quarters. The position peaked at $2.58M in Q3 2023. 120 funds tracked by Wall St. Rank hold ZNTL as of Q4 2023.

  • TwinBeech Capital reported no remaining Zentalis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • TwinBeech Capital sold 128,859 Zentalis Pharmaceuticals shares in Q4 2023, an estimated $2.58M.
  • TwinBeech Capital first reported a position in Zentalis Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • TwinBeech Capital's Zentalis Pharmaceuticals position peaked at $2.58M in Q3 2023.
  • 120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2023.

Based on TwinBeech Capital's 13F filing for Q4 2023, filed 14 Feb 2024.